ranitidine accord 300 mg filmom obalené tablety
accord healthcare polska sp. z o.o., poľsko - ranitidín - 09 - antacida (vrÁtane antiulcerosnych lieČiv)
allospes 300 mg tablety
accord healthcare polska sp. z o.o., poľsko - alopurinol - 29 - antirheumatica, antiphlogistica, antiuratica
allospes 100 mg tablety
accord healthcare polska sp. z o.o., poľsko - alopurinol - 29 - antirheumatica, antiphlogistica, antiuratica
escitalopram accord 20 mg filmom obalené tablety
accord healthcare polska sp. z o.o., poľsko - escitalopram - 30 - antidepressiva
epivir
viiv healthcare bv - lamivudín - hiv infekcie - antivirotiká na systémové použitie - epivir je indikovaný ako súčasť kombinovanej antiretrovírusovej liečby ľudskej imunodeficiencie (hiv)-dospelých a detí infikovaných.
lamivudine teva pharma b.v.
teva b.v. - lamivudín - hiv infekcie - antivirotiká na systémové použitie - lamivudin teva pharma b. je indikovaná ako súčasť antiretrovírusovej kombinovanej liečby na liečbu dospelých a detí infikovaných vírusom ľudskej imunodeficiencie (hiv).
ecomectin horse paste 18,7 mg/g, perorálna pasta pre kone
eco animal health europe, Írsko - pst.
vidaza
bristol-myers squibb pharma eeig - azacitidín - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastické činidlá - vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with: intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification. vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for hsct with aml with >30% marrow blasts according to the who classification.
exemestane accord 25 mg filmom obalené tablety
accord healthcare limited - exemestán - 44 - cytostatica
azacitidine celgene
celgene europe bv - azacitidín - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - antineoplastické činidlá - azacitidine celgene is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with:intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification,aml with >30% marrow blasts according to the who classification.